Sanofi and Regeneron said that drug candidate Itepekimab didn’t meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares down

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab following contrasting outcomes from two Phase III studies. The companies plan to discuss the results with regulatory agencies before determining the future of the IL-33 inhibitor.